Home Featured Page 231

Featured

Latest

The Psychedelic News Feed: January 26 – Febraury 1, 2026

Q3 2025: Oregon Psilocybin Services Update

Patient Safety After a Death: What Transparency Can and Cannot Do

January 2026 Psychedelic Bill Round-up

The Psychedelic News Feed: January 19 – 25, 2025

Field Trip Health Ltd. Announces Launch Of “Kap Co-Operative” Program, Enabling...

Mindset Pharma Announces its Next Generation Novel 5-MeO-DMT Psychedelic Analogs Demonstrate...

MindMed and BioXcel Therapeutics Publish an International Patent Application Describing a...

Filament Health Files 20th Patent Application Including Three International PCT Applications

What Is the ‘Collective Unconscious’ and How Can It Help Us...

Comparing Psilocybin Mushrooms and Truffles: How Are They Different?

PT260 – Benjamin Mudge – Ayahuasca and Bipolar: Pathways to a...

Red Light Holland and Creso Pharma Agree to Terminate Merger

Biotech Veteran David Kideckel Joins the Board of PharmaDrug

Psychedelic Bulletin: California Decrim. Bill Put on Pause; MindMed Inks Real-World...

1...230231232...307 Page 231 of 307

EDITOR PICKS

The Psychedelic News Feed: January 26 – Febraury 1, 2026

Q3 2025: Oregon Psilocybin Services Update

Patient Safety After a Death: What Transparency Can and Cannot Do

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

The Psychedelic News Feed: January 26 – Febraury 1, 2026

Q3 2025: Oregon Psilocybin Services Update

Patient Safety After a Death: What Transparency Can and Cannot Do

January 2026 Psychedelic Bill Round-up

The Psychedelic News Feed: January 19 – 25, 2025

Field Trip Health Ltd. Announces Launch Of “Kap Co-Operative” Program, Enabling...

Mindset Pharma Announces its Next Generation Novel 5-MeO-DMT Psychedelic Analogs Demonstrate...

MindMed and BioXcel Therapeutics Publish an International Patent Application Describing a...

Filament Health Files 20th Patent Application Including Three International PCT Applications

What Is the ‘Collective Unconscious’ and How Can It Help Us...

Comparing Psilocybin Mushrooms and Truffles: How Are They Different?

PT260 – Benjamin Mudge – Ayahuasca and Bipolar: Pathways to a...

Red Light Holland and Creso Pharma Agree to Terminate Merger

Biotech Veteran David Kideckel Joins the Board of PharmaDrug

Psychedelic Bulletin: California Decrim. Bill Put on Pause; MindMed Inks Real-World...

EDITOR PICKS

The Psychedelic News Feed: January 26 – Febraury 1, 2026

Q3 2025: Oregon Psilocybin Services Update

Patient Safety After a Death: What Transparency Can and Cannot Do

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY